Egle, Alexander
Steurer, Michael
Melchardt, Thomas
Weiss, Lukas
Gassner, Franz Josef
Zaborsky, Nadja
Geisberger, Roland
Catakovic, Kemal
Hartmann, Tanja Nicole
Pleyer, Lisa
Voskova, Daniela
Thaler, Josef
Lang, Alois
Girschikofsky, Michael
Petzer, Andreas
Greil, Richard
Funding for this research was provided by:
Celgene
Roche
FWF (I 2795)
Oncotyrol
Article History
Received: 19 March 2018
Accepted: 21 May 2018
First Online: 4 June 2018
Change Date: 23 June 2018
Change Type: Correction
Change Details: The original version of this article contained a mistake. The name of Tanja Nicole Hartman should have been Tanja Nicole Hartmann. The original article has been corrected.
Compliance with ethical standards
: This study was approved by the ethics committee of the state of Salzburg on July 30, 2008 (protocol number: 415-E/966) and by the ethics committee of each individual participating centre.
: A.E. reports speaker’s fees, travel support and research support from Celgene and Roche and consulting fees from Celgene outside the submitted work. R.Gr. reports personal fees and other from Bristol-Myers-Squibb; grants, personal fees and other from Cephalon; grants and personal fees from Amgen, Mundipharma, Genentech and Pfizer; personal fees from Eisai, Merck, Janssen-Cilag, Novartis, AstraZeneca, Boehringer Ingelheim, Roche and Sanofi Aventis; grants and other from Celgene and grants from GSK and Ratiopharm outside the submitted work. A.P. reports personal fees from Roche and Clegene outside the submitted work. M.G. reports personal fees from Basilea, MSD, Roche, Otsuka, Lilly, Merck, Celgene and Lipomed and non-financial support from Bayer, Amgen and Celgen outside the submitted work. M.S. reports personal fees from Roche and Celgene outside the submitted work. All other authors have no competing interests.